Welcome to our dedicated page for AKU news (Ticker: AKU), a resource for investors and traders seeking the latest updates and insights on AKU stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AKU's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AKU's position in the market.
Glassbeam, Inc. has appointed Rhonda Longmore-Grund to its Board of Directors. She brings valuable experience from her tenure as President & CEO of Alliance Healthcare Services, now part of Akumin (NASDAQ: AKU). Longmore-Grund's role is expected to enhance Glassbeam's capabilities in data and predictive analytics for medical equipment. Her expertise in operational efficiencies and data-driven decisions aligns with Glassbeam's vision for growth, particularly in the US and international markets.
Akumin Inc. (NASDAQ: AKU) will host a conference call on November 10, 2022, at 8:30 a.m. Eastern Time to discuss its third quarter 2022 financial results, which will be released on November 9, 2022. Participants can join via dial-in or webcast, with access details provided on their website. Akumin offers outpatient diagnostic imaging services and cancer care solutions across the U.S., servicing approximately 1,000 hospitals. The company emphasizes its commitment to efficient healthcare delivery through advanced technology.
Akumin Inc. (NASDAQ: AKU) has successfully completed its change of incorporation from Ontario, Canada, to Delaware, USA, effective September 30, 2022. This process, termed 'Domestication,' was approved by Akumin's shareholders on June 30, 2022. Following this change, Akumin will continue to trade under the stock symbol 'AKU' on both NASDAQ and the Toronto Stock Exchange. The move aims to align Akumin with the General Corporation Law of Delaware, enhancing its operational framework. Further details are available on EDGAR and SEDAR.
Akumin Inc. (NASDAQ: AKU) has announced significant personnel changes and a transformation program aimed at enhancing operations and financial stability. The company has terminated CFO William Larkin's employment and appointed David Kretschmer as Interim CFO. Akumin has also sold certain accounts receivables for approximately $30 million, improving liquidity and reducing days sales outstanding. Pro forma cash position post-sale stands at $69 million. The company is seeking to optimize patient access, customer engagement, and employee well-being through this transformation.
Akumin Inc. (NASDAQ: AKU) announced its financial results for the second quarter ended June 30, 2022, highlighting a substantial revenue growth of $192.1 million, up 176.5% year-over-year, primarily due to the acquisition of Alliance HealthCare Services. Adjusted EBITDA surged 212.7% to $38.2 million, reflecting strong operational performance amidst industry challenges. However, the company reported a net loss of $26.1 million, compared to a loss of $6.9 million in the prior year. Management remains optimistic about achieving 2022 financial goals despite decreased capital expenditures.
Akumin Inc. (NASDAQ: AKU) will conduct a conference call on August 10, 2022, at 8:30 a.m. Eastern Time to discuss its second-quarter 2022 financial results, which will be available on August 9, 2022. Akumin provides diagnostic imaging and oncology services to approximately 1,000 hospitals across 48 states. The company is recognized as a leading partner for healthcare systems in the U.S., focusing on efficiency and effective patient care through advanced technology. More information can be found on their official website.
Akumin Inc. (NASDAQ: AKU) held its annual general and special meeting on June 30, 2022, with 52,829,002 shares represented, about 59.0% of outstanding shares. All director nominees were overwhelmingly approved, with Thomas Davies receiving 99.93% support. The appointment of Ernst & Young, LLP as external auditors was also approved. Notably, shareholders authorized a move of incorporation from Ontario, Canada, to Delaware, USA, and a reverse stock split of up to one new share for every four old shares, as detailed in the management proxy circular dated May 17, 2022.
Akumin reported a significant revenue increase of $186.3 million for Q1 2022, up 191.2% from $64.0 million in Q1 2021, driven by the acquisition of Alliance HealthCare Services. Revenue rose 3.8% from Q4 2021. Despite the positive revenue growth, net loss widened to $26.4 million compared to $2.5 million in the previous year, and loss per share grew to $0.35. Adjusted EBITDA was $32.0 million, a 247.9% increase from last year. Management expressed confidence in achieving 2022 financial guidance despite ongoing risks from Omicron disruptions.
Akumin Inc. (NASDAQ: AKU) will host a conference call on May 11, 2022, at 8:30 a.m. Eastern Time to discuss its first quarter 2022 financial results. The results will be released on May 10, 2022. Participants can join the call by registering at this link or by accessing the webcast at here. A replay will be available until May 18, 2022. Akumin offers diagnostic imaging and oncology services across the U.S., with approximately 200 imaging locations and partnerships with about 1,000 hospitals.
Akumin Inc. (NASDAQ: AKU) has filed a registration statement with the SEC to allow its Board to change the company's jurisdiction from Ontario to Delaware. This move aims to streamline operations and reduce costs associated with Canadian corporate laws, as the company has no Canadian operations. If approved, the Domestication will only be implemented if deemed beneficial for Akumin and its shareholders. The announcement underscores Akumin's strategic focus on improving operational efficiency and enhancing its competitive position in the U.S. medical services market.